Advancing precision medicine for Parkinson’s

Traditional medicine often uses a one-size-fits-all approach.

Precision medicine aims to tailor treatment to an individual, guided by factors like genetics, environment, and lifestyle, so treatments can be more effective and have fewer side effects.

A biomarker is a measurable sign of a disease or a body process ideally found through a simple test (like blood or urine).

Biomarkers can help identify Parkinson’s earlier, track progression, and measure whether a treatment is working in clinical trials.

Develop a better understanding of the causes of Parkinson’s symptom diversity and complexity. Because Parkinson’s is a very complex condition with multiple genetic risks and no single known cause, subtyping of individuals with Parkinson’s is key to developing targeted drug therapies.

Using clinical phenotypes to identify biomarkers and develop diagnostic tools and provide the prediction of treatment response and enable patient stratification to improve clinical trials of drugs targeting their underlying biological mechanisms.

Construct and share patient-centric disease models including patient-derived stem cells, organoids and assembloids, that reflect Parkinson’s diversity. A major reason that potential new drugs fail in clinical trials is that they are based on Parkinson’s models that don’t replicate the disease complexity.

Bringing together leaders in drug discovery and development, we will build a pipeline to identify targets and develop disease-modifying precision medicines based on our new disease subtypes and models.